[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells

Oncogene volume 34, pages 681–690 (2015)Cite this article

Subjects

Abstract

Metastatic growth in breast cancer (BC) has been proposed as an exclusive property of cancer stem cells (CSCs). However, formal proof of their identity as cells of origin of recurrences at distant sites and the molecular events that may contribute to tumor cell dissemination and metastasis development are yet to be elucidated. In this study, we analyzed a set of patient-derived breast cancer stem cell (BCSC) lines. We found that in vitro BCSCs exhibit a higher chemoresistance and migratory potential when compared with differentiated, nontumorigenic, breast cancer cells (dBCCs). By developing an in vivo metastatic model simulating the disease of patients with early BC, we observed that BCSCs is the only cell population endowed with metastatic potential. Gene-expression profile studies comparing metastagenic and non-metastagenic cells identified TAZ, a transducer of the Hippo pathway and biomechanical cues, as a central mediator of BCSCs metastatic ability involved in their chemoresistance and tumorigenic potential. Overexpression of TAZ in low-expressing dBCCs induced cell transformation and conferred tumorigenicity and migratory activity. Conversely, loss of TAZ in BCSCs severely impaired metastatic colonization and chemoresistance. In clinical data from 99 BC patients, high expression levels of TAZ were associated with shorter disease-free survival in multivariate analysis, thus indicating that TAZ may represent a novel independent negative prognostic factor. Overall, this study designates TAZ as a novel biomarker and a possible therapeutic target for BC.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.

    Article  CAS  Google Scholar 

  2. Saini V, Shoemaker RH . Potential for therapeutic targeting of tumor stem cells. Cancer Sci 2010; 101: 16–21.

    Article  CAS  Google Scholar 

  3. Kakarala M, Wicha MS . Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26: 2813–2820.

    Article  Google Scholar 

  4. Maugeri-Sacca M, Vigneri P, De Maria R . Cancer stem cells and chemosensitivity. Clin Cancer Res 2011; 17: 4942–4947.

    Article  CAS  Google Scholar 

  5. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB . Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009; 8: 806–823.

    Article  CAS  Google Scholar 

  6. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345–349.

    Article  CAS  Google Scholar 

  7. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85–89.

    Article  CAS  Google Scholar 

  8. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539–544.

    Article  CAS  Google Scholar 

  9. Harvey KF, Zhang X, Thomas DM . The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246–257.

    Article  CAS  Google Scholar 

  10. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147: 759–772.

    Article  CAS  Google Scholar 

  11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.

    Article  CAS  Google Scholar 

  12. Perrone G, Gaeta LM, Zagami M, Nasorri F, Coppola R, Borzomati D et al. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas. PLoS One 2012; 7: e43110.

    Article  CAS  Google Scholar 

  13. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111–115.

    Article  CAS  Google Scholar 

  14. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504–514.

    Article  CAS  Google Scholar 

  15. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506–5511.

    Article  CAS  Google Scholar 

  16. Grefte S, Vullinghs S, Kuijpers-Jagtman AM, Torensma R, Von den Hoff JW . Matrigel but not collagen I, maintains the differentiation capacity of muscle derived cells in vitro. Biomed Mater 2012; 7: 055004.

    Article  CAS  Google Scholar 

  17. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253–1270.

    Article  CAS  Google Scholar 

  18. Zhao B, Lei QY, Guan KL . The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008; 20: 638–646.

    Article  CAS  Google Scholar 

  19. Lladser A, Sanhueza C, Kiessling R, Quest AF . Is survivin the potential Achilles' heel of cancer? Adv Cancer Res 2011; 111: 1–37.

    Article  CAS  Google Scholar 

  20. Yin D, Chen W, O'Kelly J, Lu D, Ham M, Doan NB et al. Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer 2010; 127: 2257–2267.

    Article  CAS  Google Scholar 

  21. Chaffer CL, Weinberg RA . A perspective on cancer cell metastasis. Science 2011; 331: 1559–1564.

    Article  CAS  Google Scholar 

  22. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1–22.

    Article  CAS  Google Scholar 

  23. Morris PG, McArthur HL, Hudis CA . Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 2009; 10: 967–981.

    Article  CAS  Google Scholar 

  24. Lai D, Ho KC, Hao Y, Yang X . Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71: 2728–2738.

    Article  CAS  Google Scholar 

  25. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H . Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11: 1154–1159.

    CAS  Google Scholar 

  26. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S . Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009; 11: R46.

    Article  Google Scholar 

  27. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288: 99–106.

    Article  CAS  Google Scholar 

  28. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615–5621.

    Article  CAS  Google Scholar 

  29. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 2007; 356: 217–226.

    Article  CAS  Google Scholar 

  30. D'Amico L, Patane S, Grange C, Bussolati B, Isella C, Fontani L et al. Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature. Br J Cancer 2013; 108: 2525–2536.

    Article  CAS  Google Scholar 

  31. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ . Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008; 26: 729–735.

    Article  Google Scholar 

  32. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28: 2426–2436.

    Article  CAS  Google Scholar 

  33. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 2592–2598.

    Article  CAS  Google Scholar 

  34. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 2012; 19: 768–778.

    Article  CAS  Google Scholar 

  35. Pagliuca A, Valvo C, Fabrizi E, di Martino S, Biffoni M, Runci D et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene 2012; 32: 4806–4813.

    Article  Google Scholar 

  36. Bonci D, Cittadini A, Latronico MV, Borello U, Aycock JK, Drusco A et al. 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 2003; 10: 630–636.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Associazione Italiana Ricerca sul Cancro (AIRC) grants IG-10254 (MT) and IG 13431 (RDM) for financial support. We are grateful to Giuseppe Loreto for figure editing, Michele Signore and Mario Falchi for confocal acquisitions.

Author information

Author notes

  1. M Bartucci and R Dattilo: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy

    M Bartucci, R Dattilo, C Moriconi, A Pagliuca, M Patrizii & M Biffoni

  2. Regina Elena National Cancer Institute, Rome, Italy

    M Mottolese, G Federici, A Di Benedetto, F Sperati, M Maugeri-Saccà & R De Maria

  3. Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy

    M Todaro & G Stassi

  4. Department of Surgical Sciences, ‘La Sapienza’ University, Rome, Italy

    M I Amabile

  5. Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, ‘La Sapienza’ University, Rome, Italy

    E Pilozzi

  6. Department of Histology, Microbiology and Medical Biotechnologies, University of Padua School of Medicine, Padua, Italy

    S Piccolo

Authors
  1. M Bartucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Dattilo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Moriconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Pagliuca
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Mottolese
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Federici
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Di Benedetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Todaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Stassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Sperati
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M I Amabile
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Pilozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M Patrizii
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Biffoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Maugeri-Saccà
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Piccolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. R De Maria
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Bartucci.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartucci, M., Dattilo, R., Moriconi, C. et al. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34, 681–690 (2015). https://doi.org/10.1038/onc.2014.5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2014.5

Keywords

This article is cited by

Search

Advanced search

Quick links